HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer.Kogawa, Takahiro; Fouad, Tamer M; Liu, Diane D; Wu, Jimin; Shen, Yu; Masuda, Hiroko; Fujii, Takeo; Chavez-MacGregor, Mariana; Alvarez, Ricardo H; Hortobagyi, Gabriel N; Valero, Vicente; Ueno, Naoto T.Oncologist; 21(1): 21-7, 2016 Jan.150.Molecular Phenotype, Multigene Assays, and the Locoregional Management of Breast Cancer.Braunstein, Lior Z; Taghian, Alphonse G.Semin Radiat Oncol; 26(1): 9-16, 2016 Jan.151.The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics.Anders, Carey K; Abramson, Vandana; Tan, Tira; Dent, Rebecca.Am Soc Clin Oncol Educ Book; 35: 34-42, 2016.152.Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers.Yue, Yong; Astvatsaturyan, Kristine; Cui, Xiaojiang; Zhang, Xiao; Fraass, Benedick; Bose, Shikha.PLoS One; 11(3): e0149661, 2016.153.The cancer genetics and pathology of male breast cancer.Deb, Siddhartha; Lakhani, Sunil R; Ottini, Laura; Fox, Stephen B.Histopathology; 68(1): 110-8, 2016 Jan.154.Signatures of breast cancer metastasis at a glance.Karagiannis, George S; Goswami, Sumanta; Jones, Joan G; Oktay, Maja H; Condeelis, John S.J Cell Sci; 129(9): 1751-8, 2016 May 1.155.Prognostic Value of Circulating Tumor Cells Identified Before Surgical Resection in Nonmetastatic Breast Cancer Patients.Hall, Carolyn S; Karhade, Mandar G; Bowman Bauldry, Jessica B; Valad, Lily M; Kuerer, Henry M; DeSnyder, Sarah M;Lucci, Anthony.J Am Coll Surg; 223(1): 20-9, 2016 Jul.156.Role of the androgen receptor in triple-negative breast cancer.Rampurwala, Murtuza; Wisinski, Kari B; O'Regan, Ruth.Clin Adv Hematol Oncol; 14(3): 186-93, 2016 Mar.157.Insulin Receptor Substrate Adaptor Proteins Mediate Prognostic Gene Expression Profiles in Breast Cancer.Becker, Marc A; Ibrahim, Yasir H; Oh, Annabell S; Fagan, Dedra H; Byron, Sara A; Sarver, Aaron L; Lee, Adrian V; Shaw, Leslie M; Fan, Cheng; Perou, Charles M; Yee, Douglas.PLoS One; 11(3): e0150564, 2016.158.Association between Mutation and Expression of TP53 as a Potential Prognostic Marker of Triple-Negative Breast Cancer.Kim, Ji-Yeon; Park, Kyunghee; Jung, Hae Hyun; Lee, Eunjin; Cho, Eun Yoon; Lee, Kwang Hee; Bae, Soo Youn; Lee, Se Kyung; Kim, Seok Won; Lee, Jeong Eon; Nam, Seok Jin; Ahn, Jin Seok; Im, Young-Hyuck; Park, Yeon Hee.Cancer Res Treat; 48(4): 1338-1350, 2016 Oct.159.Ki-67 is required for maintenance of cancer stem cells but not cell proliferation.Cidado, Justin; Wong, Hong Yuen; Rosen, D Marc; Cimino-Mathews, Ashley; Garay, Joseph P; Fessler, Abigail G;Rasheed, Zeshaan A; Hicks, Jessica; Cochran, Rory L; Croessmann, Sarah; Zabransky, Daniel J; Mohseni, Morassa;Beaver, Julia A; Chu, David; Cravero, Karen; Christenson, Eric S; Medford, Arielle; Mattox, Austin; De Marzo, Angelo M;Argani, Pedram; Chawla, Ajay; Hurley, Paula J; Lauring, Josh; Park, Ben Ho.Oncotarget; 7(5): 6281-93, 2016 Feb 2.160.Prognostic significance of PD-L1 and PD-L2 in breast cancer.Baptista, Mauricio Z; Sarian, Luis Otavio; Derchain, Sophie F M; Pinto, Glauce A; Vassallo, Jose.Hum Pathol; 47(1): 78-84, 2016 Jan.161.The expression of MAGE-C1 and MAGE-C2 in breast cancer and their clinical significance.Hou, Shuyun; Sang, Meixiang; Zhao, Lianmei; Hou, Ran; Shan, Baoen.Am J Surg; 211(1): 142-51, 2016 Jan.162.Identification of novel biomarkers associated with poor patient outcomes in invasive breast carcinoma.Canevari, Renata A; Marchi, Fabio A; Domingues, Maria A C; de Andrade, Victor Piana; Caldeira, Jose R F; Verjovski-Almeida, Sergio; Rogatto, Silvia R; Reis, Eduardo